-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CLS-12311 in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLS-12311 in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLS-12311 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Torsemide ER in Resistant Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Torsemide ER in Resistant Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Torsemide ER in Resistant Hypertension Drug Details: Torsemide (Soaanz) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AV-101 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AV-101 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AV-101 in Epilepsy Drug Details: AV-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lotilaner in Meibomian Blepharitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lotilaner in Meibomian Blepharitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lotilaner in Meibomian Blepharitis Drug Details: Lotilaner (Xdemvy) belongs to a member...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AV-101 in Neuropathic Pain (Neuralgia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AV-101 in Neuropathic Pain (Neuralgia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AV-101 in Neuropathic Pain (Neuralgia) Drug Details: AV-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AV-101 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AV-101 in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AV-101 in Major Depressive Disorder Drug Details: AV-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Torsemide ER in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Torsemide ER in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Torsemide ER in Congestive Heart Failure (Heart...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Furosemide in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Furosemide in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Furosemide in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
CL-Viaduct Solar PV Park
CL-Viaduct Solar PV Park is a solar PV project located in Pennsylvania, United States. The project is owned and developed by BCD Project Holdings 1 LLC. The project is currently under construction. Empower your strategies with our CL-Viaduct Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Company Insights
Morgan Stanley – Digital Transformation Strategies
Morgan Stanley Digital Transformation Strategies Overview Morgan Stanley is utilizing AI and machine learning to improve its wealth and asset management operations and other operational processes. AI, big data, cloud, and blockchain are among the key technologies under focus for the company. The annual ICT spending of Morgan Stanley was estimated at $4.6 billion in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and network and communications from vendors. Morgan Stanley is utilizing AI...